The National Institutes of Health (NIH) announced yesterday that it is issuing nearly $32 million in grants for the development of strategies to analyze and leverage biomedical data sets.
The National Institutes of Health (NIH) announced yesterday that it is issuing nearly $32 million in grants for the development of strategies to analyze and leverage biomedical data sets. The grants are part of NIH’s Big Data to Knowledge (BD2K) initiative, launched in December 2013. BD2K is funded from all 27 NIH institutes and centers, as well as the NIH Common Fund.
According to NIH, the collection of data from biomedical research, including DNA sequencing and imaging, is increasing beyond researchers’ ability to use the data. NIH intends for the BD2K awards to “support the development of new approaches, software, tools, and training programs to improve access to these data and the ability to make new discoveries using them.”
“Data creation in today’s research is exponentially more rapid than anything we anticipated even a decade ago,” said NIH Director Francis S. Collins, MD, PhD, in a press release. “Mammoth data sets are emerging at an accelerated pace in today’s biomedical research and these funds will help us overcome the obstacles to maximizing their utility. The potential of these data, when used effectively, is quite astounding.”
NIH funding will establish 12 centers that will each tackle specific data science challenges and provide support for creating a scientific community-based consortium to develop approaches for the creation of a data discovery index, data science training, and workforce development. The centers will be set up as follows:
More information about the recipients of the new grants may be found on NIH’s website at http://bd2k.nih.gov/FY14.html.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.